1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Renal Stones/Calculi Global Clinical Trials Review, H2, 2016

Renal Stones/Calculi Global Clinical Trials Review, H2, 2016

Summary

GlobalData's clinical trial report, “Renal Stones/Calculi Global Clinical Trials Review, H2, 2016" provides an overview of Renal Stones/Calculi clinical trials scenario. This report provides top line data relating to the clinical trials on Renal Stones/Calculi. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Renal Stones/Calculi Global Clinical Trials Review, H2, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Renal Stones/Calculi to Genito Urinary System And Sex Hormones Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Renal Stones/Calculi to Genito Urinary System And Sex Hormones Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Renal Stones/Calculi Therapeutics Clinical Trials 27
Prominent Drugs 28
Clinical Trial Profile Snapshots 29
Appendix 112
Abbreviations 112
Definitions 112
Research Methodology 113
Secondary Research 113
About GlobalData 114
Contact Us 114
Disclaimer 114
Source 115

List of Tables
Renal Stones/Calculi Therapeutics, Global, Clinical Trials by Region, 2016* 6
Renal Stones/Calculi Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Renal Stones/Calculi Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Renal Stones/Calculi Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Renal Stones/Calculi Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Renal Stones/Calculi Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Renal Stones/Calculi Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12
Renal Stones/Calculi Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Renal Stones/Calculi to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2016* 14
Renal Stones/Calculi Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Renal Stones/Calculi Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Renal Stones/Calculi to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2016* 17
Renal Stones/Calculi Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Renal Stones/Calculi Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Renal Stones/Calculi Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Renal Stones/Calculi Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Renal Stones/Calculi Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Renal Stones/Calculi Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Renal Stones/Calculi Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Renal Stones/Calculi Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Renal Stones/Calculi Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Renal Stones/Calculi Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Renal Stones/Calculi Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Renal Stones/Calculi Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Renal Stones/Calculi Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Renal Stones/Calculi Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Renal Stones/Calculi Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Renal Stones/Calculi Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Renal Stones/Calculi Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Renal Stones/Calculi Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12
Renal Stones/Calculi Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Renal Stones/Calculi to Genito Urinary System And Sex Hormones Clinical Trials, G7 Countries (%), 2016* 14
Renal Stones/Calculi Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Renal Stones/Calculi Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Renal Stones/Calculi to Genito Urinary System And Sex Hormones Clinical Trials, E7 Countries (%), 2016* 17
Renal Stones/Calculi Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Renal Stones/Calculi Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Renal Stones/Calculi Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Renal Stones/Calculi Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Renal Stones/Calculi Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Renal Stones/Calculi Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Renal Stones/Calculi Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Renal Stones/Calculi Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Renal Stones/Calculi Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Renal Stones/Calculi Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Renal Stones/Calculi Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 113

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Human Epidermal growth factor Receptor type 2 (HER2-) breast cancer is the second ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...

PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.